Kilitch Drugs (India) share news, announcements and annual reports
NSE: KILITCHBSE: 524500Pharmaceuticals & BiotechnologySmall Cap
Kilitch Drugs (India) Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1994 on BSE, Sep 2010 on NSE
Last close ₹214.97up ₹7.44 (3.59%)BSE ₹214.55
Share price at the NSE close on 28 Oct 2026. Previous close ₹207.53.
28 Oct: open ₹206.50, high ₹223.80, low ₹206.10
52-week range of traded prices to 28 Oct 2026
₹117.25Low, 30 Mar 2026₹267.90High, 7 Oct 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹752 Cr1,776th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 25.01
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.69
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 12.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 8.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.32
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 72,07150.4% delivered
Kilitch Drugs (India) disputes and clarifications
20 filed, newest first.
Mar 2023
10 Mar · Legal
Exchange has sought clarification from Kilitch Drugs (India) Limited for the quarter ended 31-Dec-2022 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Limited Review Report/ Independent Auditor's Report is not in the format prescribed by SEBI The response of the Company is awaited.
Apr 2022
11 Apr · Legal
The exchange asked on 8 Apr 2022
Aug 2021
20 Aug · Legal
Exchange has sought clarification from Kilitch Drugs (India) Limited with respect to announcement dated 13-Aug-2021, regarding Appointment of Statutory Auditor. On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment).The response of the Company is awaited.
Jul 2021
23 Jul · Legal
Significant movement in price has been observed in Kilitch Drugs (India) Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.
Jul 2020
28 Jul · Legal
Exchange has sought clarification from Kilitch Drugs (India) Limited for the quarter ended 31-Mar-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Consolidated audited review report not submitted. The response of the Company is awaited.
Jun 2020
15 Jun · Legal
The exchange asked on 12 Jun 2020
Apr 2020
9 Apr · Legal
The exchange asked on 8 Apr 2020
Dec 2019
18 Dec · Legal
Exchange had sought clarification from Kilitch Drugs (India) Limited with respect to announcement dated 09-Dec-2019, regarding " Kilitch Drugs (India) Limited has informed the Exchange regarding a press release dated December 09, 2019, titled "Kilitch Drugs to set-up second green field Project in Ethiopia at an investment of USD 5 mn".". The Company on REPLY_DATE has clarified as below: Dear Sir,Sub: Reply to the Clarification sought with respect to an announcement regarding a press release titled Kilitch Drugs to set-up second green field Project in Ethiopia at an investment of USD 5 Millions.With reference to your query by email dated 17th December, 2019 seeking clarification with respect to an announcement submitted to the Exchange dated Dec 09, 2019, regarding a press release titled Kilitch Drugs to set-up second green field Project in Ethiopia at an investment of USD 5 Millions, please be informed as under, 1. Existing Capacity:- We are putting up plant no. 1 at Ethiopia for Cephalosporin injection, the project is in final stage of the Completion and we shall commence the production in the first quarter of 2020-21. The Green Field Project plant no. 2 is for liquid injectables like Gentamicin, Diclofenac, etc. Hence there is no comparison as such between the two plants. Plant no. 1 is for powder injectables and plant no. 2 is for liquid injectables. 2. Existing Capacity Utilization:- We have not started the production in plant no. 1, hence the query of capacity utilization does not arise. 3.Proposed capacity addition:- Plant no. 1 and plant no. 2 are separate. Plant no. 1 is for powder injectables and plant no. 2 is for liquid injectables. 4. Period within which the proposed capacity is to be added:- Plant no. 2 shall be on commercial stream by 2021-22. 5. Mode of financing:- As of the day we will finance the project from our own sources and reserves & surplus.You are requested to take the same on your record.17 Dec · Legal
Exchange has sought clarification from Kilitch Drugs (India) Limited with respect to announcement dated 09-Dec-2019 regarding a press release titled Kilitch Drugs to set-up second green field Project in Ethiopia at an investment of USD 5 mn.On basis of above the Company is required to clarify following:1. Existing capacity;2. Existing capacity utilization;3. Proposed capacity addition;4. Period within which the proposed capacity is to be added;5. Mode of financing;The response of the Company is awaited.
May 2018
29 May · Legal
Exchange has sought clarification from Kilitch Drugs (India) Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone Reconciliation of Equity not submitted -2. Consolidated Reconciliation of Equity not submitted The response of the Company is awaited.
Sep 2017
21 Sep · Legal
Exchange has sought clarification from Kilitch Drugs (India) Limited with respect to announcement dated 20-Sep-2017, regarding "Outcome of Board Meeting held on September 20, 2017. The board of directors of the company have hereby approved the allotment of 2100000 warrants on preferential basis and have appointed Ms. Jill Gada, as the company secretary w.e.f. September 20, 2017.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is awaited.
Aug 2017
24 Aug · Legal
Exchange has sought clarification from Kilitch Drugs (India) Limited with respect to announcement dated 23-Aug-2017, regarding "Outcome of Board Meeting held on August 23, 2017.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is awaited.